MedPath
HSA Approval

BIBAG (5008 DESIGN) POWDER FOR HAEMODIALYSIS

SIN13822P

BIBAG (5008 DESIGN) POWDER FOR HAEMODIALYSIS

BIBAG (5008 DESIGN) POWDER FOR HAEMODIALYSIS

July 2, 2010

FRESENIUS MEDICAL CARE SINGAPORE PTE. LTD.

FRESENIUS MEDICAL CARE SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantFRESENIUS MEDICAL CARE SINGAPORE PTE. LTD.
Licence HolderFRESENIUS MEDICAL CARE SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

POWDER, FOR SOLUTION

EXTRACORPOREAL

Manufacturer Information

FRESENIUS MEDICAL CARE SINGAPORE PTE. LTD.

Fresenius Medical Care SMAD

Active Ingredients

Sodium Bicarbonate

100 %

Sodium bicarbonate

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

BIBAG (5008 DESIGN) POWDER FOR HAEMODIALYSIS - HSA Approval | MedPath